Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer, Guidelines from National Institute for Clinical Excellence

59789.pdf

http://www.nice.org.uk/nicemedia/live/13773/59789/59789.pdf

Lung Cancer, Genomics, Prevention & Treatment

• CDC Feature: Lung cancer awareness- Smoking causes 80 to 90 percent of cases of lung cancer. Don't smoke, and avoid secondhand smoke 
• CDC Blog: Smoking and Genetics- No easy answers
• HuGENavigator Phenopedia  search reveals 1043 genes have been reportedly associated with increased risk of lung cancer
• HuGENavigator GWAS integrator search reveals 84 hits from genomewide association studies
• Tier 1 Genomic Test: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer, Guidelines from National Institute for Clinical Excellence (UK)  [PDF 189.11 KB] and the National Comprehensive Cancer Network  [PDF 1.47 MB]